SCHEMBL4548501

SCHEMBL4548501

Cc1nc2cscc2[nH]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8277825 0.71 PARP1 (0.55)
SCHEMBL13041691 0.70 ALDH1A1 (0.59)
SCHEMBL12213872 0.69 MAPT (0.68)
SCHEMBL15767763 0.67 NPC1 (0.41)
SCHEMBL1038167 0.65 FABP6 (0.63)
SCHEMBL13947194 0.65 ALDH1A1 (0.53)
SCHEMBL111276 0.65 RAB9A (0.66)
SCHEMBL2745140 0.65 GPR84 (0.48)
SCHEMBL2745080 0.65 GPR84 (0.48)
SCHEMBL2744745 0.65 NPC1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2585462-B1 FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2020-02-26 EP disclosed
US-20170165248-A1 SOLID DOSAGE FORM COMPRISING PROTON PUMP INHIBITOR AND SUSPENSION MADE THEREOF ASTRAZENECA AB (SE) 2017-06-15 US disclosed
US-20170165248-A1 SOLID DOSAGE FORM COMPRISING PROTON PUMP INHIBITOR AND SUSPENSION MADE THEREOF ASTRAZENECA AB (SE) 2017-06-15 US disclosed
US-9580409-B2 Modulators of opioid receptors and methods of use thereof SUNOVION PHARMACEUTICALS, INC. (US) 2017-02-28 US disclosed
US-9226921-B2 Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-05 US disclosed
US-9226921-B2 Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-05 US disclosed
US-20150079186-A1 SOLID DOSAGE FORM COMPRISING PROTON PUMP INHIBITOR AND SUSPENSION MADE THEREOF ASTRAZENECA AB (SE) 2015-03-19 US disclosed
US-20150079186-A1 SOLID DOSAGE FORM COMPRISING PROTON PUMP INHIBITOR AND SUSPENSION MADE THEREOF ASTRAZENECA AB (SE) 2015-03-19 US disclosed
US-8962688-B2 Method for the treatment of gastrointestinal disorders SUCAMPO AG (CH) 2015-02-24 US disclosed
US-8962688-B2 Method for the treatment of gastrointestinal disorders SUCAMPO AG (CH) 2015-02-24 US disclosed
US-20070276006-A1 Method for the treatment of gastrointestinal disorders SUCAMPO AG 2007-11-29 US disclosed
US-20070213362-A1 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY REPLIDYNE, INC. (US) 2007-09-13 US disclosed
US-20070213362-A1 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY REPLIDYNE, INC. (US) 2007-09-13 US disclosed
WO-2007075381-A2 PHARMACEUTICAL COMPOSITIONS OF ILAPRAZOLE TAP PHARMACEUTICAL PRODUCTS, INC. (US) 2007-07-05 WO disclosed
WO-2007064932-A2 PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE BAYER HEALTHCARE LLC. (US) 2007-06-07 WO disclosed
US-7220757-B2 Compositions and methods for topical administration of 2-NH-heteroarylimidazoles REPLIDYNE, INC. (US) 2007-05-22 US disclosed
US-7220757-B2 Compositions and methods for topical administration of 2-NH-heteroarylimidazoles REPLIDYNE, INC. (US) 2007-05-22 US disclosed
US-20070053981-A1 Solid composition comprising a proton pump inhibitor ASTRAZENECA AB (SE) 2007-03-08 US disclosed
US-20070053981-A1 Solid composition comprising a proton pump inhibitor ASTRAZENECA AB (SE) 2007-03-08 US disclosed
US-7169793-B2 Process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof DR. REDDY'S LABORATORIES LIMITED (IN) 2007-01-30 US disclosed